186 related articles for article (PubMed ID: 34835153)
21. Effectiveness of Pfizer/BioNTech and Sinopharm COVID-19 vaccines in reducing hospital admissions in prince Hamza hospital, Jordan.
Al-Momani H; Aldajah K; Alda'ajah E; ALjafar Y; Abushawer Z
Front Public Health; 2022; 10():1008521. PubMed ID: 36211700
[TBL] [Abstract][Full Text] [Related]
22. Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines.
Adjobimey T; Meyer J; Sollberg L; Bawolt M; Berens C; Kovačević P; Trudić A; Parcina M; Hoerauf A
Front Immunol; 2022; 13():917905. PubMed ID: 35799790
[TBL] [Abstract][Full Text] [Related]
23. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study).
Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Wittmann I; Molnár GA; Nagy D; Müller V; Bogos K; Nagy P; Kenessey I; Wéber A; Polivka L; Pálosi M; Szlávik J; Rokszin G; Müller C; Szekanecz Z; Kásler M
Front Immunol; 2022; 13():919408. PubMed ID: 35935993
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of Homologous and Heterologous Vaccine Applications on SARS-CoV-2 Omicron Variant: Cohort of Manisa Celal Bayar University Healthcare Workers].
Çiçek K; Özkaya Y; Eser E; Buran ZC; Öztürk Arıkan ZÖ; Akçalı S; Erbay Dündar P; Cengiz Özyurt B; Şenol Akar Ş; Özer D; Karadağ Yalçın F
Mikrobiyol Bul; 2023 Apr; 57(2):238-251. PubMed ID: 37067208
[TBL] [Abstract][Full Text] [Related]
26. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
[TBL] [Abstract][Full Text] [Related]
27. Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behcet's syndrome.
Ozdede A; Nohut OK; Atli Z; Tok YT; Guner S; Yilmaz E; Ucar D; Uygunoglu U; Hamuryudan V; Seyahi E
Rheumatol Int; 2022 Oct; 42(10):1741-1750. PubMed ID: 35779083
[TBL] [Abstract][Full Text] [Related]
28. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
29. RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia.
Batmunkh B; Otgonbayar D; Shaarii S; Khaidav N; Shagdarsuren OE; Boldbaatar G; Danzan NE; Dashtseren M; Unurjargal T; Dashtseren I; Dagvasumberel M; Jagdagsuren D; Bayandorj O; Biziya B; Surenjid S; Togoo K; Bat-Erdene A; Narmandakh Z; Choijilsuren G; Batmunkh U; Soodoi C; Boldbaatar EA; Byambatsogt G; Byambaa O; Deleg Z; Enebish G; Chuluunbaatar B; Zulmunkh G; Tsolmon B; Gunchin B; Chimeddorj B; Dambadarjaa D; Sandag T
PLoS One; 2023; 18(12):e0295167. PubMed ID: 38064430
[TBL] [Abstract][Full Text] [Related]
30. Antibody Response after Homologous and Heterologous Prime-Boost COVID-19 Vaccination in a Bangladeshi Residential University Cohort.
Adnan N; Haq MA; Akter S; Sajal SMSA; Islam MF; Mou TJ; Jamiruddin MR; Jubyda FT; Islam MS; Tuli JF; Liza SM; Hossain S; Islam Z; Ahmed S; Khandker SS; Hossain R; Ahmed MF; Khondoker MU; Azmuda N; Parvez MAK
Vaccines (Basel); 2024 Apr; 12(5):. PubMed ID: 38793733
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.
Ergun T; Hosgoren Tekin S; Apti Sengun O; Akin Cakici O; Seckin D; Adiay C; Enul H; Yilmaz S; Ay P; Haklar G; Sili U
Vaccine; 2023 Jun; 41(29):4287-4294. PubMed ID: 37277251
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm.
Anvari E; Ghamar Talepoor A; Eshkevar Vakili M; Karimi N; Ataollahi M; Najafi G; Kabelitz D; Ahmadi I; Kalantar K
Iran J Immunol; 2022 Sep; 19(3):321-329. PubMed ID: 36190385
[TBL] [Abstract][Full Text] [Related]
33. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
[TBL] [Abstract][Full Text] [Related]
34. Analysis of IgG, IgA and IgM antibodies against SARS-CoV-2 spike protein S1 in convalescent and vaccinated patients with the Pfizer-BioNTech and CanSinoBio vaccines.
Melgoza-González EA; Hinojosa-Trujillo D; Reséndiz-Sandoval M; Mata-Haro V; Hernández-Valenzuela S; García-Vega M; Bravo-Parra M; Arvizu-Flores AA; Valenzuela O; Velázquez E; Soto-Gaxiola A; Gómez-Meza MB; Pérez-Jacobo F; Villela L; Hernández J
Transbound Emerg Dis; 2022 Jul; 69(4):e734-e745. PubMed ID: 34655457
[TBL] [Abstract][Full Text] [Related]
35. Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5-11 Years.
Joseph G; Klein E; Lustig Y; Weiss-Ottolenghi Y; Asraf K; Indenbaum V; Amit S; Kriger O; Gilboa M; Levy Y; Pessach IM; Kreiss Y; Regev-Yochay G; Stein M
Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36423049
[TBL] [Abstract][Full Text] [Related]
36. Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals.
Al-Tamimi M; Tarifi AA; Qaqish A; Abbas MM; Albalawi H; Abu-Raideh J; Salameh M; Khasawneh AI
PLoS One; 2023; 18(2):e0281689. PubMed ID: 36787317
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the Immunogenicity and Protective Efficacy of Various SARS-CoV-2 Vaccines among Healthcare Workers: Are Our White Coat Armies Protected?
Souan L; Sughayer MA; Abualhour MM; Siag M; Al-Badr S; Al-Atrash T
Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632398
[TBL] [Abstract][Full Text] [Related]
38. IgG level of the third booster dose for mRNA of SARS-CoV-2 vaccines among Iraqi healthcare workers.
Rasheed WS; Sarkees AN
Medicine (Baltimore); 2023 Oct; 102(40):e35444. PubMed ID: 37800839
[TBL] [Abstract][Full Text] [Related]
39. Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAE-An Observational Study.
Ganesan S; Al Ketbi LMB; Al Kaabi N; Al Mansoori M; Al Maskari NN; Al Shamsi MS; Alderei AS; El Eissaee HN; Al Ketbi RM; Al Shamsi NS; Saleh KM; Al Blooshi AF; Cantarutti FM; Warren K; Ahamed F; Zaher W
Front Public Health; 2022; 10():876336. PubMed ID: 35602146
[TBL] [Abstract][Full Text] [Related]
40. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
